DZNep Promotes Mouse Bone Defect Healing via Enhancing Both Osteogenesis and Osteoclastogenesis

Xiankun Cao

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Wenxin He

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Kewei Rong

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shenggui Xu

Fujian Medical University affiliated Mindong Hospital: Mindong Hospital of Ningde City

Zhiqian Chen

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Yuwei Liang

Sun Yat-Sen Memorial Hospital

Shuai Han

Guangxi Key Laboratory of Regenerative Medicine

Yifan Zhou

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Xiao Yang

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Hui Ma

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

An Qin

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Jie Zhao (✉ profzhaojie@126.com)

Shanghai Jiao Tong University School of Medicine <https://orcid.org/0000-0003-1000-5641>

Research

Keywords: DZNep, Osteoclast, Osteoblast, Bone defect, EZH2-H3K27me3-Wnt Signaling Pathway, EZH2-H3K27me3-Foxc1-NF-κB Signaling Pathway

Posted Date: August 27th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-815335/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Stem Cell Research & Therapy on December 1st, 2021. See the published version at <https://doi.org/10.1186/s13287-021-02670-6>.

Abstract

Background: EZH2 (Enhancer of zeste homolog 2) is a novel oncogene that can specifically trimethylate the histone H3 lysine 27 (H3K27me3) to transcriptionally inhibit the expression of downstream tumor-suppressing genes. As a small molecular inhibitor of EZH2, 3-Deazaneplanocin (DZNep) has been widely studied due to the role of tumor suppression. With the roles of epigenetic regulation of bone cells emerged in past decades, the property and molecular mechanism of DZNep on enhancing osteogenesis had been reported and attracted a great deal of attention recently. this study aims to elucidate the role of DZNep on EZH2-H3K27me3 axis and downstream factors during both osteoclasts and osteoblasts formation and the therapeutic possibility of DZNep on bone defect healing.

Methods: Bone marrow driven macrophages (BMMs) cells were cultured and their responsiveness to DZNep was evaluated by Cell Counting Kit-8, TRAP staining assay, Bone Resorption Assay, Podosome Actin Belt. Bone marrow driven mesenchymal stem cells (BMSC) were cultured and their responsiveness to DZNep was evaluated by Cell Counting Kit-8, ALP and AR staining assay. The expression of nuclear factor- κ B (NF- κ B), mitogen-activated protein kinase (MAPK), Wnt signaling pathway was determined by qPCR and western blotting. Mouse bone defect models were created, rescued by DZNep injection and the effectiveness was evaluated by X-ray and Micro-CT and Histological staining.

Results: Consistent with the previous study that DZNep enhances osteogenesis via Wnt family member 1(Wnt1), Wnt6, and Wnt10a, our results showed that DZNep also promotes osteoblasts differentiation and mineralization through the EZH2-H3K27me3-Wnt4 axis. Furthermore, we identified that DZNep promoted the receptor activator of nuclear factor- κ B (NF- κ B) ligand (RANKL)-induced osteoclast formation via facilitating the phosphorylation of IKK α / β , I κ B, and subsequently NF- κ B nuclear translocation, which credit to the EZH2-H3K27me3-Foxc1 axis. More importantly, the enhanced osteogenesis and osteoclastogenesis result in accelerated mice bone defect healing *in vivo*.

Conclusion: DZNep targeting EZH2-H3K27me3 axis facilitated the healing of mice bone defect via simultaneously enhancing osteoclastic bone resorption and promoting osteoblastic bone formation.

Background

EZH2 is a novel oncogene that emerges in recent years. Due to its histone methyltransferase activity, EZH2 can specifically trimethylate the histone H3 lysine 27 (H3K27me3) to inhibit the expression of downstream tumor-suppressive genes at the transcriptional level, which promote the proliferation and decrease the apoptosis of cancer cells [1–3]. With the roles of epigenetic regulation of bone cells emerged in past decades, the function of EZH2 in bone homeostasis has been attracting a great deal of attention recently.

Bone, a dynamic tissue, constantly undergoes the procedure of new bone formation and old bone elimination [4]. Under physiological conditions, this kind of process is inseparably balanced and coordinated by the bone-resorbing osteoclasts and bone-forming osteoblasts [5, 6]. Once pathological

damage such as defect and fracture occur, both osteogenesis and subsequent osteoclastogenesis are initiated to facilitate bone healing [7, 8]. There are several precedent studies with divergence but demonstrating the importance of EZH2-H3K27me3 axis in osteoclast differentiation and mesenchymal stem cells (MSCs). Fang and colleagues reported that EZH2 was recruited to the IRF8 promoter regions after RANKL stimulation to deposit H3K27me3 and downregulate IRF8 expression, and thus exerted a positive effect on osteoclastogenesis[9]. Adamik and colleagues further showed that RANKL triggers EZH2 translocation into the nucleus where it represses negative regulators of osteoclastogenesis such as MafB, Irf8, and Arg1[10]. However, one study indicated that the inhibition of EZH2-H3K27me3 axis resulted in the transcriptional up-regulation of Foxc1 [11]. Foxc1 had been verified to induce the nuclear translocation of NF-κB through promoting the phosphorylation of IκB both in mice airway smooth muscle cells and human basal-like breast cancer cells [12, 13] and the PI3K/AKT signaling pathway in Ovalbumin-Induced Asthmatic Mice [14]. Moreover, the nuclear translocation of activated NF-κB was widely acknowledged to upregulate the key downstream regulators like the nuclear factor of activated T cells c1 (NFATc1) [15] and c-Fos [16], which plays important roles in osteoclast formation [17]. Similarly in MSCs, Hemming and colleagues generated mesenchymal cell-specific conditional knock-out mice of EZH2 gene using Prx-cre drive, and demonstrated that Ezh2 +/- and -/- mice exhibited thinner cortical bone and decreased mechanical strength compared to the wild-type control [18]. While Jing H and colleagues reported that DZNep, a small molecular compound universally known as an inhibitor of EZH2 [2, 19, 20], shifts the differentiation of MSCs from adipocytes to osteoblasts by removing the inhibitory effect of EZH2-H3K27me3 axis on the Wnt signaling pathway [21]. To sum up, the role of EZH2-H3K27me3 axis on bone homeostasis is still controversy and the explicit mechanism remains to be further explored.

DZNep was extensively studied because of its suppressive roles on EZH2 in tumors, such as malignant peripheral nerve sheath tumor, prostate cancer, head and neck squamous cell carcinoma, gastric cancer, and acute myeloid leukemia (AML) [22–26]. As previous mentioned, the enhancing osteogenesis property of DZNep via EZH2-H3K27me3-Wnt axis had been reported. Nevertheless, there is few research discussing the role of DZNep on osteoclasts. Whether and how the EZH2-H3K27me3 axis play an important role during osteoclastogenesis after DZNep treatment is still absence currently. Moreover, drugs and compounds regulate the formation of osteoclasts [27] and osteoblasts [28] have been widely studied for treatment of the bone defect and fracture. Exploring the potential therapeutic effect of DZNep on bone defect via regulating both osteogenesis and osteoclastogenesis *in vivo* also has great clinical significance.

Taken together, this study aims to elucidate the role of DZNep on EZH2-H3K27me3 axis and downstream factors during both osteoclasts and osteoblasts formation and the therapeutic possibility of DZNep on bone defect healing.

Methods

Reagents and Antibodies

The S-adenosine homocysteine and EZH2 inhibitor DZNep was purchased from ApexBio (Houston, TX, USA), and was dissolved in phosphate buffer saline (PBS) as a stock solution at the concentration of 5 mM. Fetal bovine serum (FBS) was bought from Gibco BRL (Sydney, Australia), minimal essential medium alpha (α -MEM) was bought from Hyclone (Logan, UT, USA), and penicillin/streptomycin was purchased from Gibco BRL (Gaithersburg, MD, USA). Recombinant mouse RANKL and M-CSF were obtained from R&D (Minneapolis, MN, USA). The Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Molecular Technology (Japan). The TRAP staining kits were bought from Sigma-Aldrich (St. Louis, MO, USA). The SYBR® Premix Ex Taq™ II and Prime Script RT reagent Kit were obtained from Takara Biotechnology (Otsu, Shiga, Japan). The primary antibodies against β -actin, LaminB, ERK, phospho-ERK (Tr202/Tyr204), JNK, phospho-JNK (Tr183/Tyr185), p38, phospho-p38, IKK β , I κ B α , P65, phospho-IKK α / β , phospho-I κ B α , phospho-P65, EZH2, H3K27me3, GSK-3 β , phospho-GSK-3 β (ser9), and the secondary antibody, were bought from Cell Signaling Technology (CST, Danvers, MA, USA). The primary antibodies against NFATc1, c-FOS were purchased from Absin Bioscience Inc (Shanghai, China). All the antibody mentioned are rabbit anti-mouse.

Bone marrow-derived macrophages (BMMs) preparation and Cytotoxicity Assay

Primary BMMs were obtained from whole bone marrow of male 6-week-old C57BL/6 mice. In brief, cells were extracted from the tibiae and femurs bone marrow and suspended in complete α -MEM (α -MEM supplemented with 30 ng/ml M-CSF, 10% FBS, and 1% penicillin/streptomycin). Then, the cell cultures were kept in a humid environment at 37 °C with 5% CO₂ until they reached 90% confluence. The Cytotoxic effects of DZNep on BMMs were then determined by the CCK-8 kit. Specifically, the BMMs were seeded into 96-well plates in triplicate at the density of 8×10^3 cells/well in presence of 100 μ L complete α -MEM for 24 hours. After that, the cells were treated with increasing concentration of DZNep (control, 3.125, 6.25, 12.5, 25, 50, 100, 200nM) for 24, 48, and 96 hours. After treatment, 100 μ L medium contained 10% CCK-8 buffer was added to the wells and incubated in the dark at 37 °C for 2 hours. The absorbance was then detected at 450 nm wavelength (650 nm reference) on a microplate reader.

Osteoclast differentiation and TRAP Staining Assay

To evaluate the role of DZNep on osteoclastogenesis, BMMs were seeded into, in triplicate, a 96-well plate at the density of 8×10^3 cells/well with complete α -MEM for one day. Afterward, the culture medium was replaced by the complete α -MEM containing different concentrations of DZNep (control, 3.125, 6.25, 12.5, and 25 nM) and RANKL (50 ng/ml) to stimulate osteoclast differentiation. Cells untreated with DZNep were included as the control group. For EZH2 gene knockdown studies, the cells were transfected with virus constructed of different EZH2 short hairpin RNA (shRNA) and negative control shRNA by mixed with polybrene (final concentration of 10 μ g/ml) for 48 hours. The transfection mixture was then replaced by complete α -MEM added with puromycin for 24 hours and BMMs were then seeded into a 96-well plate at

the density of 10×10^4 cells/well with complete α -MEM. The culture medium was then replaced every 2 days until the matured osteoclasts could be observed in the plate. The plate was then washed by PBS 1 times and fixed with 4% paraformaldehyde for 15 min. TRAP staining was performed immediately without light at 37 °C for 30 min. Moreover, the BMMs treated with or without DZNep for various days were also analyzed. An optical microscope (Olympus, Tokyo, Japan) was used to image the Photos, and the TRAP-positive cells with more than three nuclei were considered osteoclasts and were quantified the area and number using the ImageJ software (NIH, Bethesda, MD, USA).

Bone Resorption Assay

To explore the effect of DZNep on the function of osteoclast, BMMs on complete α -MEM were seeded at the density of 1×10^4 cells/well, in triplicate, on the Osteo Assay Surface plates (Corning, NY, USA). After thirty-six hours, the culture medium were replaced by complete α -MEM, with RANKL (50 ng/mL), and various doses of DZNep (control, 6.25, 12.5, and 25 nM). For EZH2 gene knockdown studies, the cells were transfected with virus constructed of different EZH2 short hairpin RNA (shRNA) and negative control shRNA by mixed with polybrene (final concentration of 10ug/ml) for 48 hours. The transfection mixture was then replaced by complete α -MEM added with puromycin for 24 hours and the survived BMMs were seeded into a 96-well plate, in triplicate, at a density of 1×10^4 cells/well. The medium need be constantly replaced until the osteoclast had matured for 1 day. The 5% sodium hypochlorite were used to wash the wells for 3 min to remove the cells. The total area of resorption was photographed, and then calculated by Image J software (NIH, Bethesda, MD, USA).

Immunofluorescence of Podosome Actin Belt

BMMs in complete α -MEM with or without 25nM DZNep were seeded in 6-well plates at a density of 1×10^5 cells/well and cultured for 6 days. Once the matured osteoclast could be observed, the plate was washed by PBS and then fixed with 4% paraformaldehyde. The 10 minutes 0.2% Triton X-PBS was then performed for permeabilizing. After three times washing by PBS, FITC-labeled phalloidin was added for 1 hour in darkness to bounds with the cells F-actin ring. The nuclei were stained at RT for 5 minutes without light by 4', 6-diamidino-2-phenylindole (DAPI). After the final PBS wash, the perimeter of the actin ring could be observed by the fluorescence microscope (Leica), and analyzed using Image J software (NIH, Bethesda, MD, USA).

Cultivation, differentiation, and mineralization of osteoblasts

To identify the effect of DZNep on osteogenesis, bone marrow-derived mouse mesenchymal stem cells were firstly seeded into the 48-well plates for one day at a density of 5×10^4 cells/well. Then the medium was changed by Low-glucose DMEM with 15% FBS, 5 mM β -glycerophosphate, 50 μ g/mL ascorbic acid,

10-7mM dexamethasone, and various concentration of DZNep (0, 12.5, 25, 50, and 100 nM). The medium was changed twice a week. On day 7 and day 28, cells were stained by using BCIP/NBT kit (Beyotime, Shanghai, China) to observed the percent of Alkaline phosphatase (ALP) positive cells and 1% Alizarin red S solution (Solarbio, Beijing, China) to visualize the extracellular matrix calcium deposition.

Quantitative real-time PCR Analysis

BMMs were cultured in 6-well plates at the density of 3×10^5 cells/well in α -MEM supplemented with M-CSF (30 ng/ml), RANKL (50 ng/ml). The cells were then treated with or without 25nM DZNep for 0, 1, 3, 5 days, or with various concentrations of DZNEP (0, 6.25, 25 nM) for 5 days. Once the culture completed, the Axygen RNA Miniprep Kit (Axygen, Union City, CA, USA) was used to extract the total RNA. BMSC were seeded in a 6-well plate at a number of 4×10^5 cells/well and treated with 0, 25, 50, 100 nM of DZNep combined with osteoblast cultured medium for 24 hours, or with or without 100nM DZNep combined with osteoblast cultured medium for 0 and 7 days. Once the culture completed, the Axygen RNA Miniprep Kit (Axygen, Union City, CA, USA) was used to extract the total RNA. After reverse transcription to obtain cDNA from the RNA template by using the Prime Script RT reagent Kit was finished. The real-time PCR assay was subsequently performed by using the SYBR® Premix Ex Taq™ II on an ABI 7500 Sequencing Detection System (Applied Biosystems, Foster City, CA). Specifically, total volume of 10 μ l liquid consisted by 5 μ l of SYBR® Premix Ex Taq™ II, 1 μ l of diluted cDNA, 0.4 μ l of mixed forward and reverse primer, and 3.6 μ l of ddH2O was added into each hole of 384 PCR plate. Conditions of the 40 cycles were: 95 °C for 5 s and 60 °C for 30 s. The melting curves and reverse transcription PCR (RT-PCR) were the methods to detect the specificity of amplification product. Each target's quantity, run in triplicate, was normalized to Actin Beta (Actb). Mouse Actb, CathepsinK (Ctsk), tartrate-resistant acid phosphatase/acid phosphatase (Trap/Acp5), nuclear factor of activated T-cells c1 (Nfatc1), AP-1 Transcription Factor Subunit (c-Fos), Mus musculus ATPase, H⁺ transporting, lysosomal V0 subunit D2 (Atp6v0d2), calcitonin receptor (Calcr), RUNX Family Transcription Factor 2 (Runx2), Wnt1, Wnt10a, Wnt4, Osteocalcin (Ocn), Wnt6, Osteopontin (Opn), and collagen type 1 alpha 1 (Col1a1), primer sequences are listed in Table 1.

Table 1

Primer pairs sequences against osteoclast gene used in qPCR.

Mouse Gene	Forward 5' à 3'	Reverse 5' à 3'
<i>Trap/Acp5</i>	CAAAGAGATCGCCAGAACCG	GAGACGTTGCCAAGGTGATC
<i>Ctsk</i>	CTTCCAATACGTGCAGCAGA	TCTTCAGGGCTTTCTCGTTC
<i>Atp6v0d2</i>	GCAGAGCTGTACTTCAATGTGG	TAGTCCGTGGTCTGGAGATG
<i>Calcr</i>	TCTGCGTTCCTGAGAACACC	AAGGCGCTCTAATGGCACTT
<i>Nfatc1</i>	TGCTCCTCCTCCTGCTGCTC	GCAGAAGGTGGAGGTGCAGC
<i>c-Fos</i>	CCAGTCAAGAGCATCAGCAA	AAGTAGTGCAGCCCGGAGTA
<i>Runx2</i>	TGGCCGGGAATGATGAGAAC	GGATGAGGAATGCGCCCTAA
<i>Ocn</i>	GCGCTCTGTCTCTCTGACCT	TTTGTAGGCGGTCTTCAAGC
<i>Opn</i>	TTTGTAGGCGGTCTTCAAGC	GTGAGATTCTGTCAGATTCATCCG
<i>Col1a1</i>	TAAGGGTCCCCAATGGTGAGA	GGGTCCCTCGACTCCTACAT
<i>Wnt1</i>	ATAGCCTCCTCCACGAACCT	GATGAACGCTGTTTCTCGGC
<i>Wnt4</i>	GAGCAACTGGCTGTACCTGG	GGAAGTGGTACTGGCACTCC
<i>Wnt6</i>	GGTCACTCAAGCCTGTTCCA	CCGAAGTCCACATCGTCTCC
<i>Wnt10a</i>	CTGAACACCCGGCCATACTTC	CTGAACACCCGGCCATACTTC
<i>Foxc1</i>	CACTCGGTGCGGGAAATGT	GTGCGGTACAGAGACTGACTG
<i>Actb</i>	ACAGCAGTTGGTTGGAGCAA	ACGCGACCATCCTCCTCTTA

Western Blotting Analysis

To explore the variation of the proteins on long-term activated signaling, BMMs were cultured in α -MEM containing M-CSF (30 ng/ml) and RANKL (50 ng/ml) at a density of 2×10^5 cells/well on 6-well plates. After 24 hours, the BMMs were treated with or without 25 nM DZNep for 0, 1, 3, and 5 days, and total protein was obtained respectively on these specific time points. To determine the effect of DZNep on the protein of short-time activated phosphorylated, RAW264.7 cells were cultured in α -MEM at a density of 5×10^5 cells/well on 6-well plates. One day later, the cells were treated with the serum-free α -MEM in the presence or absence of DZNEP for 3h, then stimulated with 50 ng/mL RANKL for 0, 10, 20, 30, and 60 mins. To identify the role of DZNep on the EZH2 and H3K27me2 in osteoblasts, BMSC cells were cultured with α -MEM supplemented 10% FBS at a density of 5×10^5 cells/well on 6-well plates. After one day, different doses of DZNEP were treated on the cells for 4h, then osteoblast cultured medium was added for another 24 hours. Afterward, the cells were washed by the phosphate-buffered saline (PBS), total protein of the cells was extracted by using lysate consisting of protease, phosphorylase inhibitor cocktail (Sigma-Aldrich), and radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime, Shanghai, China). After centrifuged at $13,000 \times g$ for 15 min, the bicinchoninic acid (BCA) assay was then used to detect the

concentrations of the protein in the supernatant. Finally, the supernatant proteins were diluted by 5×SDS-sample loading buffer and separated by 4-20% SDS-PAGE before transferred to nitrocellulose filter membranes (GE Healthcare Life Sciences, Pittsburgh, PA, USA). The 5% skim milk dissolved in 1 × TBST (Tris-buffered saline with Tween 20) were used to block the membranes at room temperature for 1 h. And the primary antibodies (β -actin, 1:1000; LaminB, 1:1000; ERK, 1:1000; p-ERK, 1:1000; JNK, 1:1000; p-JNK, 1:1000; p38, 1:1000; p-p38, 1:1000; IKK β , 1:1000; p-IKK α/β , 1:500; I κ B α , 1:1000; p-I κ B α , 1:1000; P65, 1:1000; p-P65, 1:500; NFATc1, 1:500; c-FOS, 1:1000; EZH2, 1:1000; H3K27me3, 1:1000; GSK-3 β , 1:1000; and p-GSK-3 β , 1:1000;) were then incubated with the membranes together overnight at 4 °C. After TBST wash for 3 times, the secondary fluorescence antibodies were incubated without light for 1 h at room temperature and the reactivity was visualized by using Odyssey V3.0 image scanning (Li-COR. Inc., Lincoln, NE, USA).

Osteoblasts and osteoclasts co-cultivation

For the osteoblasts and osteoclasts co-culture system, calvarial OB isolated from day 1-3 pups were cultured for 24 hours. Then the calvarial OB with complete α -MEM (α -MEM supplemented with 10% FBS, 1% penicillin/streptomycin) were seeded into 24 well plates at a density of 2×10^4 cells/well. After 3 days of cultivation, the medium was replaced by the complete α -MEM containing 50ng/ml Ascorbic acid and 5mM β -glycerophosphate. On the same day, bone marrow monocytes were isolated from bone marrow and cultured in 10cm dish. Another 3 days later, BMMs were seeded at a density of 4×10^4 cells/well into the 24-well plate containing the calvarial OB, and the α -MEM supplemented with 15% FBS, 1% penicillin/streptomycin, 1, 25-dihydroxy vitamin D3 (10 nM; CSN), and PGE2 (1 μ M; CSN). After changed every 3 days for 2 times of the culture medium, the cells were then fixed and stained to observe the percent of the positive ALP staining area using a kit according to the manufacturer's instructions (Beyotime, Shanghai, China). The percent of area was then quantified using Image J.

Tibia cortical and trabecular bone defect mice model

This study was totally carried out in terms of the guidelines for the Ethical Conduct in the Care and Use of Nonhuman Animals in Research by the American Psychological Association. Moreover, the Animal Care and Experiment Committee of Shanghai Jiao Tong University School of Medicine approved the animal experiment of this research.

The tibia cortical and trabecular bone defect mice model was established to determine the bone healing effect of DZNep *in vivo*. Firstly, all mice (twelve 8-week-old C57/BL6 male mice (approximate weight 20 ± 2 g)) were anesthetized by 2% isoflurane, the right tibia was exposed and muscles were dissociated. Then a pilot hole was first made with a burr drill point in the proximal tibia, but away from the growth plate to some extent. Then the hole was enlarged with a 1 mm reamer. Afterward, the mice were average divided into two groups: (1) DZNep group (injection with 100 μ g/kg DZNep); (2) Sham group (injection with 1× PBS). Two days after operation, 1× PBS for sham group and DZNep for treatment group were

intraperitoneally injected every two days during next two week. All mice were finally euthanized after experiment, and whole tibia bones were separated. After fixed in 4% paraformaldehyde for 24 hours, the 75% ethanol were then used to soak the specimens for further histological and radiographic analysis.

Micro-Computed Tomography scanning

High-resolution micro-CT (μ CT-100, SCANCO Medical AG, Switzerland) was used to perform the micro-computed tomography (CT) scanning. Scans were conducted in 75% ethanol and used an X-ray intensity of 200 uA, an X-ray tube potential of 70 kVp, and an integration time of 300 ms. For analysis bone mass of defect section, a region of defect section trabecular bone was contoured, starting from the first defect section level away from proximal end of the distal femoral growth plate. Femoral trabecular bone was thresholded at 211 per mille. The indicators of bone microstructure (bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecula number (Tb.N), trabecula separation (Tb.Sp), and bone surface/bone volume (BS/BV)) were measured by software (Version: 6.5-3, SCANCO Medical AG, Switzerland) through evaluating and analyzing the three-dimensional region of interest (ROI).

Histological analysis

After fixing in 4% paraformaldehyde for 48 hours, the 10% EDTA was used to decalcify the fixed tibias for 21 days. Then the tissues were processed by dehydrating in different concentrations of ethanol, infiltrating with xylene, and embedding with paraffin. Hematoxylin and eosin (H&E) and TRAP staining were then performed on these prepared histological sections. As for immunofluorescent staining, slices were processed in a sequence of deparaffinization, hydration, antigen retrieval, permeabilization, blocking, primary antibody incubation (OCN, USA, Affinity; dilution 1:100), secondary antibody incubation, and nuclear staining finally. The specimens were observed and photographed under the high-quality microscope (Leica DM4000B). Each sample's number of osteoclasts, TRAP-positive multinucleated osteoclasts per field (Oc.S/BS) were calculated.

Statistical analysis

The results were analyzed by using Prism 8 (GraphPad Software Inc, San Diego, CA, USA). The data were uniformly presented in the form of median and interquartile range. The comparisons between experimental and control groups were made by the 2-tailed, unpaired Student's t test, One-way ANOVA with turkey's post hoc-test. Statistical significant were determined to be at * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.

Results

DZNep promoted RANKL-Induced Osteoclastogenesis *In Vitro*

The cytotoxicity effect of DZNep (Figure 1A) on primary BMMs was investigated. As shown in Figure 1B, no cytotoxicity was found at the concentration of 25nM. The inhibitory concentration (IC50) value of DZNep was examined to be 325.7nM at 96 hours (Figure 1C). To further explore the role of DZNep on osteoclastogenesis *in vitro*, BMMs were cultured with RANKL, M-CSF, and DZNep at concentrations Less than or equal to 25nM. A little number of multinucleated trap-positive osteoclasts were observed in the control group after 5-day stimulation. However, the experimental groups increased the number of mature osteoclasts in a DZNep dose-dependent manner. The number of mature osteoclast nuclei also increased in a dose-dependent manner significantly when compared with the control group (Figure 1D, E). Furthermore, we added 25nM DZNep into the osteoclast inductive medium at specific time points. Comparing with the control group, DZNep increased the number of osteoclasts at the middle stage (day 3-5). More osteoclasts with more than 10 nuclei could be found at the middle stage and final stage of osteoclast differentiation (day 3-5, day 5-7) compared with control (Figure 1F, G). Therefore, DZNep enhanced osteoclastogenesis *in vitro*.

DZNep increased osteoclast resorption capacity *In Vitro*

To determine the function of DZNep on osteoclastic bone resorption, different concentrations of DZNep were added after primary BMMs were plated on the hydroxyapatite-coated Osteo Assay plates (Figure 2A). Bone resorption pits were markedly induced. When treated with DZNEP at 25 nM, more than 30% bone resorption area was observed compared with the control group (Figure 2B).

DZNep induced osteoclast podosome belt formation *In Vitro*

Cytoskeletal podosome belt formation is an indispensable part of osteoclastic bone resorption [29]. Here we examined the role of DZNep on the formation of osteoclast cytoskeletal podosome belt. DZNep promoted the podosome actin belt formation of osteoclast at the concentration of 25 nM compared with the control group (Figure 2C, D). To sum up, these data suggested that DZNep substantially increased osteoclastic bone resorption capacity along with osteoclast podosome belt formation *in vitro*.

DZNep upregulated the osteoclast-related genes expression *in vitro*

In order to better comprehend the effect of DZNep on osteoclasts, we analyzed the expression of several vital osteoclast-related genes by real-time PCR (qPCR). The genes markedly upregulated during the

process of osteoclast formation were measured, such as Trap, Ctsk, Atp6v0d2. After DZNep was added at the dose of 25 nM, these genes expression was significantly enhanced in a time-dependent manner (Figure 2E). Meanwhile, the expression of Calcr, c-FOS, and Nfatc1 along with genes mentioned above were upregulated in a dose-dependent manner after DZNep was added (Figure 2F). Together, these data further confirmed that DZNEP promotes osteoclastogenesis *in vitro*.

DZNep promoted osteoclastogenesis by activating the NF- κ B signaling pathway

To clarify the detailed mechanisms about the DZNep-induced promotion of osteoclast formation. We first investigated the effect of DZNep on the c-FOS and NFATc1 which is the downstream of c-FOS and has been proved to be one of the most significant transcription factors for osteoclast differentiation. BMMs were cultured in medium added with RANKL, with or without DZNep for 0, 1, 3, and 5 days. The expression of c-FOS and NFATc1 were both gradually increased over time in the control group and were further enhanced after DZNep was added at the concentration of 25 nM (Figure 3A, B). Also, the c-FOS and NFATc1 expression were upregulated after BMMs were treated with RANKL, with DZNep in a concentration-dependent manner for 5 days (Figure 3C, D). We further examined whether the enhanced c-FOS and NFATc1 expression in osteoclast were also through the activated NF- κ B pathway. Consistent with our hypothesis, our western blotting analyses and immunofluorescence staining of cytoplasm and nuclear proteins showed the enhancement of NF- κ B nuclear translocation upon DZNep treatment (Figure 3E, F). Previous literature demonstrated that DZNep could upregulate the NF- κ B nuclear translocation by promoting the I κ B phosphorylation in mice airway smooth muscle cells and human basal-like breast cancer cells [12, 13]. After that, we examined the transduction factors of classical NF- κ B signaling pathways, which mainly include the inhibitor of nuclear factor kappa-B kinase (IKK), and inhibitor of nuclear factor kappa-B (I κ B), and NF- κ B. We observed the phosphorylation of IKK, I κ B, and p65 were further promoted over time with DZNep treatment (Figure 4A, B, and C). We also examined the influence of DZNep on another important signaling pathways, the MAPKs signaling pathways, for osteoclast formation. Our data shown that the phosphorylation of JNK, p38 and ERK were comparable in both the control and the DZNep -treated groups (Figure 4D, E). Collectively, these results indicated that DZNep promoted the phosphorylation of IKK, and I κ B, accelerated the degradation of I κ B and further stimulated the p65 nuclear translocation during osteoclast formation.

DZNep activated the NF- κ B signaling pathway through the EZH2-H3K27me3-Foxc1 axis

As previously introduced that the inhibition of EZH2 and subsequently down-regulated H3K27me3 resulted in the transcriptional up-regulation of Foxc1, which activates the phosphorylation of the I κ B [11-13]. We examined the role of DZNep on the EZH2-H3K27me3-Foxc1 axis. BMMs were cultured in medium with RANKL, with or without DZNep for 0, 1, 3, and 5 days. The EZH2 and H3K27me3 expression were

decreased at a time-manner after DZNep was added at the concentration of 25 nM when comparing with the control group (Figure 5A, B). Also, the up-regulated mRNA expression of Foxc1 was observed in a concentration-dependent manner after BMMs RANKL, and DZNep treatment for 5 days (Figure 5C). As predicted, our further EZH2 silencing experiment results were in accordance with that inhibition of EZH2 induce the expression of Foxc 1, which could be most obviously observed on the group treated with shRna-2 of EZH2 (Figure 5D, E). Moreover, the experimental groups added with shRNA also increased the area and number of mature osteoclasts when compared with the negative shRNA treated group (Figure 5F, G). Matching with it, the bone resorption capacity was enhanced in the shRNA treated group (Figure 5H, I). These results illustrated that DZNep activated the NF- κ B signaling pathway through the EZH2-H3K27me3-Foxc1 axis, which mediating the enhanced osteoclastogenesis.

DZNep induced Osteogenesis *In Vitro*

We further investigated the effect of DZNep on osteogenesis. We first performed the cytotoxicity experiment of DZNep on primary BMSC at 12, 48, and 96 hours. Results showed that no cytotoxicity was found at the concentration of 100nM (Figure 6A). After that, osteoblasts cultured medium were added on primary BMSC for 7 days and 28 days, with different concentrations of DZNep. ALP staining showed that osteoblast differentiation was promoted by DZNep, especially on the concentration of 50nM (Figure 6B, C). Further Alizarin red staining also demonstrated that osteoblast mineralization was enhanced in a dose-dependent manner (Figure 6D, E). Besides, co-culture system which contained both osteoclasts and pre-osteoblasts also revealed that DZNep still preserves the effect of promoting osteogenesis (Figure 6F, G). Taken together, DZNep promoted Osteogenesis *in vitro*.

DZNep promoted Osteogenesis through EZH2-H3K27me3-Wnt4 axis *in vitro*.

To excavate unknown mechanisms on the enhanced osteogenesis of DZNep, We firstly performed the western blotting experiment on the proteins extracted from the primary BMSC stimulated with different concentrations of DZNep for 24 hours. Results showed that the EZH2 and H3k27me3 expression were dose-dependent decreased, compared with the control group (Figure 7A-D). After that, important Wnt signaling pathway-related genes in a short time stimulation were examined by qPCR. Interestingly, Wnt4 as well as Wnt1, Wnt6a, and Wnt10, which had been reported up-regulated via the DZNep-EZH2-H3K27me3 axis, was increased in a concentration-dependent manner (Figure 7E). Moreover, the expression of these genes after the osteoblast cultured medium was added for 7 days was obviously up-regulated as well (Figure 7F). While the canonical upstream activator, the GSK-3 β , of β -catenin had no significant change on the level of phosphorylation (Supplement Figure 1). However, the downstream osteoblast-specified genes Runx2, Ocn, Opn, Col1a1 were enhanced in a time-dependent and dose-dependent manner (Figure 7G, H). To sum up, DZNep promoted Osteogenesis through the EZH2-H3K27me3-Wnt4 axis *in vitro*.

Administration of DZNep facilitated the repair of Bone defect *In Vivo*

Given the enhanced osteogenesis and osteoclastogenesis effect *in vitro*, we further examined whether DZNep can facilitate bone defect repair *in vivo*. We first examined the animal X-ray in mice treated with or without DZNep for two weeks after bone defect. Image results showed that there were more bone mineral density in the treated group when compared with the control group (Figure 8A). Consistent with the two-dimensional (2D) images, the three-dimensional (3D) reconstruction of the micro-CT scanning also indicated the accelerated repair in mice with bone defect (Figure 8B). Further quantitative analysis demonstrated that the BV/TV, and the trabecular thickness (Tb.th) were prominently increased in the treated group (Figure 8C). Moreover, the H&E-stained sections obtained from the treated group indicated more significant bone repair in comparison with the control group (Figure 8D). *In vivo* TRAP staining shown the same results as *in vitro* that the administrated-group has more number of TRAP-positive multinucleated osteoclasts compared with the vehicle-treated group (Figure 8E, F). Meanwhile, the osteocalcin (OCN) expression, which mainly represents the formation of matured osteoblasts, was also increased in the DZNep-treated group (Figure 8G). These results illustrated that administration of DZNep facilitated the repair of bone defect *In vivo*.

Discussion

DZNep was reported as a potential compound to treat many kinds of tumors. Here in our study, we demonstrated that DZNep is also effective in enhancing bone defect repair, which partly credit to the enhanced osteoblast differentiation and osteoclast-formation. Cancer bone metastasis is commonly accompanied by destruction of bone [30]. The protective effect of DZNep may further protect the bone during the treatment of tumors. Therefore, this finding may further promote the use of DZNep for bone metastasis tumors.

The balance between osteoclastic bone resorption and osteoblastic bone formation maintains the homeostasis of bone. The differentiation and mineralization of osteoblasts had been proved to be essential for fracture and bone defect healing [31]. Meanwhile, osteoclast formation facilitated late-stage callus remodeling [32]. During the past decades, many methods, like drugs, compounds, factors, and biomaterials, have been made in the treatment of bone fractures and defects [33–35]. Therefore, compounds that can enhance osteogenesis and osteoclastogenesis are required for the treatment of the bone fracture and defect. In our present research, we demonstrated that DZNep could strongly promote RANKL-Induced Osteoclastogenesis. Meanwhile, the formation of osteoclast podosome belt and bone resorption were also enhanced. The underlying mechanisms were also revealed. We primarily investigated the nuclear translocation of p-p65, which binds to the Nfatc1 promoter and induces osteoclast formation [36, 37]. Our data showed that the nuclear translocation of p-p65 was specifically activated after treated with DZNep. The canonical activation of nuclear translocation and NF- κ B p65 subunits phosphorylation began from the binding between RANKL and the receptor RANK [38]. Then the

phosphorylation of TAK1 and downstream molecules IKK β , I κ B was activated successively, which finally resulted in the I κ B proteasomal degradation and p-p65 nuclear translocation [39]. And in the study of DZNep's role on mice airway smooth muscle cells and human basal-like breast cancer cells, the NF- κ B nuclear translocation was promoted via the I κ B phosphorylation, which credited to the up-regulated transcription of Foxc1 after the inhibition of EZH2 and subsequent H3K27me3 [12, 13]. Hence, we carried out the silence experiment of EZH2 and the data demonstrated that p-IKK α/β , p-I κ B α were promoted by the DZNep-EZH2-H3K27me3-Foxc1 axis, which explained the activation and subsequent nuclear translocation of p-p65.

Furthermore, lots of factors regulated by osteoclasts, like Wnt10b, sema3a, smad1/5/8, and so on, had been widely demonstrated to mediate the differentiation and function of osteoblasts [21, 40, 41]. Although the p-p65 nuclear translocation in the osteoblast was reported to reduce osteogenesis by inhibiting the phosphorylation of Smad1/5, which promotes the osteoblast-formation by inducing Runx2 expression [42]. Our data of DZNep on enhancing osteoblast formation was in agreement with the study that differentiation of MSC cell was shifted from adipocyte cell to osteoblasts due to the activation of Wnt gene transcription (Wnt1, Wnt6, and Wnt10a) [21]. Furthermore, similar to the reported EZH2-H3K27me3-Wnt1, Wnt6, Wnt10a axis, the Wnt4 had also been demonstrated transcriptionally regulating by H3K27me3 [43, 44]. Meanwhile, the Wnt4, which has been identified to promotes osteogenesis due to the stimulated transcription of Runx2 caused by upregulated nuclear translocation of β -catenin and the expression of JNK and p38 [45], was also upregulated after the stimulation of DZNep in our research. All in all, we illustrated that the EZH2-H3K27me3-Wnt4 axis was partly contributed to the enhanced osteogenesis effect of DZNep.

Correspond to the pro-osteoclastogenic and pro-osteogenic properties *in vitro*, our animal experiments *in vivo* further identified the enhanced role of DZNep on the healing of bone defect mice model. In our study, our bone defect mice with an intraperitoneal injection of DZNep showed markedly increased bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th) by the Micro-CT analysis and H&E staining, when compared with the control group. Furthermore, our IHC staining indicated that the DZNep administration did increase the number of TRAP + Multinucleated cells and the immunofluorescence staining explicitly displayed the enhanced OCN expression on the treatment group than the control group. It means that DZNep could promote mice bone defect healing by stimulating osteoclastogenesis and osteogenesis at the same time.

However, as the earliest exploration study of the DZNep effect on osteoclasts and bone defect, our study still has several weaknesses. Firstly, further exploration of the underlying intermolecular regulation between osteoclast and osteoblast after DZNep treatment is still needed, which could better demonstrates how and why increased osteoclastic differentiation and activity at early phases can influence osteogenesis and be beneficial for bone defect closure. Secondly, it's need to be concerned that whether pharmacological therapy can fill any bone defect, such as critical-size defect. Larger size of the defect should be conducted in future experiment and the effect from pharmacological therapy in this regard should be identified. Thirdly, it is not suitable to treat patients with bone defects and fractures

before further effects in other bone sites of general body and other animal models, like the bone fracture mice model and so on, shall have evaluated.

Conclusions

Our study confirmed that DZNep effectively promotes RANKL-induced osteoclastogenesis through the the EZH2-H3K27me3-Foxc1 axis and subsequent activation of the canonical NF- κ B signaling pathway, and dependents on the EZH2-H3K27me3-Wnt4 axis to significantly enhanced osteogenesis. We also demonstrated that osteogenesis and osteoclastogenesis were both facilitated by DZNep *in vitro* and *in vivo*. In a whole, the results of this study not only indicate the great potential therapeutic effect of DZNep on bone defect, but also point out that the EZH2, in addition to an anti-tumor target, might be a momentous target in bone defect treatment by affecting osteoclast and osteoblast simultaneously.

Abbreviations

EZH2: Enhancer of zeste homolog 2

H3K27me3: trimethylamine the histone H3 lysine 27

DZNep: 3-Deazaneplanocin

BMMs: bone marrow driven macrophages

BMSC: bone marrow driven mesenchymal stem cells

NF- κ B: nuclear factor- κ B

RANKL: receptor activator of nuclear factor- κ B ligand

MAPK: mitogen-activated protein kinase

IKK: inhibitor of nuclear factor kappa-B kinase

I κ B: inhibitor of nuclear factor kappa-B

Declarations

Ethics approval and consent to participate

Animals Ethics approval were received from the Institutional Animal Ethics Review Board of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (Approval# SH9H-2020-TK194-1).

Consent for publication

Written informed consent for publication was obtained from all participants.

Availability of data and materials

All data and materials included in this study are available upon request by contact with the corresponding author

Competing interests

The authors have declared that no competing interests exist

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81572167; 81772373; 92068102); National Infrastructures for Translational Medicine (shanghai) opening topic (TMSK-2020-119); Crossover Fund of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (JYJC202015); Excellent Personnel Cultivation Project of Shanghai Ninth People's hospital, Shanghai Jiao Tong University School of Medicine (JC201801).

Authors' contributions

Jie Zhao, An Qin, and Hui Ma guided all the studies. Xiankun Cao, Wenxin He, Kewei Rong performed the experiments, organized the data, and drafted the manuscript. Shenggui Xu, Zhiqian Chen performed the statistical analysis. Yuwei Liang, Shuai Han helped to draft the manuscript. Yifan Zhou, Xiao Yang participated in its design. All authors read and approved the final manuscript.

Acknowledgement

The work was supported by grants from the National Natural Science Foundation of China (Grant No. 81572167; 81772373; 92068102); National Infrastructures for Translational Medicine (shanghai) opening topic (TMSK-2020-119); Crossover Fund of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (JYJC202015); Excellent Personnel Cultivation Project of Shanghai Ninth People's hospital, Shanghai Jiao Tong University School of Medicine (JC201801).

References

1. Pan YM, Wang CG, Zhu M, Xing R, Cui JT, Li WM, Yu DD, Wang SB, Zhu W, Ye YJ, et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. *Mol Cancer*. 2016;15(1):79.
2. Qu Y, Lu D, Jiang H, Chi X, Zhang H. EZH2 is required for mouse oocyte meiotic maturation by interacting with and stabilizing spindle assembly checkpoint protein BubR1. *Nucleic Acids Res*. 2016;44(16):7659–72.
3. Chase A, Cross NC. Aberrations of EZH2 in cancer. *Clin Cancer Res*. 2011;17(9):2613–8.
4. Compston JE, McClung MR, Leslie WD. **Osteoporosis** *Lancet*. 2019;393(10169):364–76.
5. Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. *Ther Adv Musculoskelet Dis*. 2016;8(6):225–35.
6. Yahara Y, Barrientos T, Tang YJ, Puvion-Randall V, Nadesan P, Zhang H, Gibson JR, Gregory SG, Diao Y, Xiang Y, et al. Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair. *Nat Cell Biol*. 2020;22(1):49–59.
7. Hankenson KD, Gagne K, Shaughnessy M. Extracellular signaling molecules to promote fracture healing and bone regeneration. *Adv Drug Deliv Rev*. 2015;94:3–12.
8. Kylmälä E, Nakamura M, Tuukkanen J. Osteoclasts and Remodeling Based Bone Formation. *Curr Stem Cell Res Ther*. 2016;11(8):626–33.
9. Fang C, Qiao Y, Mun SH, Lee MJ, Murata K, Bae S, Zhao B, Park-Min KH, Ivashkiv LB: **Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8.** *J Immunol* 2016, **196**(11):4452–4456.
10. Adamik J, Pulugulla SH, Zhang P, Sun Q, Lontos K, Macar DA, Auron PE, Galson DL. EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets. *J Bone Miner Res*. 2020;35(1):181–95.
11. Zheng XJ, Li W, Yi J, Liu JY, Ren LW, Zhu XM, Liu SW, Wang JH, Du GH. **EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers.** *Acta Pharmacol Sin* 2020.
12. Zhu J, Wang W, Wu X. Isorhynchophylline exerts anti-asthma effects in mice by inhibiting the proliferation of airway smooth muscle cells: The involvement of miR-200a-mediated FOXC1/NF-κB pathway. *Biochem Biophys Res Commun*. 2020;521(4):1055–60.
13. Wang J, Ray PS, Sim MS, Zhou XZ, Lu KP, Lee AV, Lin X, Bagaria SP, Giuliano AE, Cui X. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling. *Oncogene*. 2012;31(45):4798–802.
14. Liu Y, Miao Y, Gao X, Wang YY, Wang H, Zheng YW, Zhao ZY. MicroRNA-200a Affects the Proliferation of Airway Smooth Muscle Cells and Airway Remodeling by Targeting FOXC1 via the PI3K/AKT Signaling Pathway in Ovalbumin-Induced Asthmatic Mice. *Cell Physiol Biochem*. 2018;50(6):2365–89.
15. Dankbar B, Fennen M, Brunert D, Hayer S, Frank S, Wehmeyer C, Beckmann D, Paruzel P, Bertrand J, Redlich K, et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. *Nat Med*. 2015;21(9):1085–90.

16. Tanos T, Marinissen MJ, Leskow FC, Hochbaum D, Martinetto H, Gutkind JS, Coso OA. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. *J Biol Chem.* 2005;280(19):18842–52.
17. Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. *Nat Med.* 1997;3(11):1285–9.
18. Hemming S, Cakouros D, Codrington J, Vandyke K, Arthur A, Zannettino A, Gronthos S. EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling. *Faseb j.* 2017;31(3):1011–27.
19. Krämer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P, Gelse K, Beyer C, Distler A, Marquez VE, et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. *Ann Rheum Dis.* 2013;72(4):614–20.
20. Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. *Clin Cancer Res.* 2012;18(1):77–90.
21. Jing H, Liao L, An Y, Su X, Liu S, Shuai Y, Zhang X, Jin Y. Suppression of EZH2 Prevents the Shift of Osteoporotic MSC Fate to Adipocyte and Enhances Bone Formation During Osteoporosis. *Mol Ther.* 2016;24(2):217–29.
22. Zhang P, Yang X, Ma X, Ingram DR, Lazar AJ, Torres KE, Pollock RE. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. *Mol Cancer.* 2015;14:55.
23. Gannon OM, Merida de Long L, Endo-Munoz L, Hazar-Rethinam M, Saunders NA. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. *Clin Cancer Res.* 2013;19(2):428–41.
24. Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). *Clin Cancer Res.* 2012;18(15):4201–12.
25. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. *Blood.* 2009;114(13):2733–43.
26. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. *Mol Cancer.* 2011;10:40.
27. Kim BS, Yang SS, Lee J. Precoating of biphasic calcium phosphate bone substitute with atelocollagen enhances bone regeneration through stimulation of osteoclast activation and angiogenesis. *J Biomed Mater Res A.* 2017;105(5):1446–56.
28. Jiang M, Liu R, Liu L, Kot A, Liu X, Xiao W, Jia J, Li Y, Lam KS, Yao W. Identification of osteogenic progenitor cell-targeted peptides that augment bone formation. *Nat Commun.* 2020;11(1):4278.

29. Touaitahuata H, Morel A, Urbach S, Mateos-Langerak J, de Rossi S, Blangy A. Tensin 3 is a new partner of Dock5 that controls osteoclast podosome organization and activity. *J Cell Sci.* 2016;129(18):3449–61.
30. Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. *Breast Cancer Res.* 2010;12(6):215.
31. Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, Li N, Liu Y, Yang YS, Eiseman M, et al. Discovery of a periosteal stem cell mediating intramembranous bone formation. *Nature.* 2018;562(7725):133–9.
32. Liu Z, Mar KB, Hanners NW, Perelman SS, Kanchwala M, Xing C, Schoggins JW, Alto NM. A NIK-SIX signalling axis controls inflammation by targeted silencing of non-canonical NF- κ B. *Nature.* 2019;568(7751):249–53.
33. Oryan A, Alidadi S. Reconstruction of radial bone defect in rat by calcium silicate biomaterials. *Life Sci.* 2018;201:45–53.
34. Srouji S, Blumenfeld I, Rachmiel A, Livne E. Bone defect repair in rat tibia by TGF-beta1 and IGF-1 released from hydrogel scaffold. *Cell Tissue Bank.* 2004;5(4):223–30.
35. Vannucci L, Brandi ML. Healing of the bone with anti-fracture drugs. *Expert Opin Pharmacother.* 2016;17(17):2267–72.
36. Yan J, Yin Y, Zhong W, Wang C, Wang Z. CD137 Regulates NFATc1 Expression in Mouse VSMCs through TRAF6/NF- κ B p65 Signaling Pathway. *Mediators Inflamm.* 2015;2015:639780.
37. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. *Nat Rev Immunol.* 2007;7(4):292–304.
38. Mincheva S, Garcera A, Gou-Fabregas M, Encinas M, Dolcet X, Soler RM. The canonical nuclear factor- κ B pathway regulates cell survival in a developmental model of spinal cord motoneurons. *J Neurosci.* 2011;31(17):6493–503.
39. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nat Rev Mol Cell Biol.* 2007;8(1):49–62.
40. Sonoda S, Murata S, Nishida K, Kato H, Uehara N, Kyumoto YN, Yamaza H, Takahashi I, Kukita T, Yamaza T. Extracellular vesicles from deciduous pulp stem cells recover bone loss by regulating telomerase activity in an osteoporosis mouse model. *Stem Cell Res Ther.* 2020;11(1):296.
41. Iezaki T, Onishi Y, Ozaki K, Fukasawa K, Takahata Y, Nakamura Y, Fujikawa K, Takarada T, Yoneda Y, Yamashita Y, et al. The Transcriptional Modulator Interferon-Related Developmental Regulator 1 in Osteoblasts Suppresses Bone Formation and Promotes Bone Resorption. *J Bone Miner Res.* 2016;31(3):573–84.
42. Xie Z, Yu H, Sun X, Tang P, Jie Z, Chen S, Wang J, Qin A, Fan S. A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Irf1-Mediated and I κ B α -Mediated p65 Nuclear Translocation. *J Bone Miner Res.* 2018;33(4):667–78.
43. Garcia-Moreno SA, Lin YT, Futtner CR, Salamone IM, Capel B, Maatouk DM. CBX2 is required to stabilize the testis pathway by repressing Wnt signaling. *PLoS Genet.* 2019;15(5):e1007895.

44. Katoh N, Kuroda K, Tomikawa J, Ogata-Kawata H, Ozaki R, Ochiai A, Kitade M, Takeda S, Nakabayashi K, Hata K. Reciprocal changes of H3K27ac and H3K27me3 at the promoter regions of the critical genes for endometrial decidualization. *Epigenomics*. 2018;10(9):1243–57.
45. Li X, Li Z, Wang J, Li Z, Cui H, Dai G, Chen S, Zhang M, Zheng Z, Zhan Z, et al. Wnt4 signaling mediates protective effects of melatonin on new bone formation in an inflammatory environment. *FASEB J*. 2019;33(9):10126–39.

Figures

Figure 1

DZNep promoted RANKL-induced osteoclastogenesis without cytotoxic effects in vitro. (A) The structure of DZNep. (B) Cell viability of DZNep-treated BMMs was tested by CCK-8 at 24, 48, and 96 hours. (C) IC₅₀ value obtained for the activity of DZNep against BMMs. (D) BMMs were treated with different concentrations of DZNep and stimulated by M-CSF (30ng/ml) and RANKL (50ng/ml) for 5 days. Then the cells were fixed with 4% paraformaldehyde and stained for TRAP. Scale bar = 100µm. (E) Quantification of TRAP-positive multinuclear cells, number of osteoclasts, area of osteoclasts, and osteoclast size. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). (F) TRAP-positive BMMs following the treatment with 25nM DZNep for indicated days during osteoclastogenesis. Scale bar = 100µm. (G) Quantification of TRAP-positive multinuclear cells, number of osteoclasts, area of osteoclasts, and osteoclast size. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are expressed as median and interquartile range n=4-6.

Figure 2

DZNeP promoted osteoclastic bone resorption, osteoclast precursor cell fusion, and the expression of osteoclast-specific genes in vitro. (A) BMMs were seeded onto the hydroxyapatite-coated Osteo Assay plates and cultured with M-CSF (30 ng/mL), RANKL (50 ng/mL), and with 0, 6.25, 12.5, and 25 nM DZNeP for 5 days. Scale bar = 200 μ m. (B) Quantification of bone resorption area were performed by ImageJ. (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$). (C) The perimeter of the actin ring was measured using Image J. (D) Representative immunofluorescence images for Podosome actin belt formation. Scale bar =

20 μ m. (*p < 0.05; **p < 0.01; ***p < 0.001). (E) Expression of the osteoclast-specific genes *Trap*, *Ctsk*, and *Atp6v0d2* in BMMs treated with 25 nM DZNep, M-CSF (30ng/mL), and RANKL (50ng/mL) for 0, 1, 3, and 5 days. (F) Expression of the osteoclast-specific genes *Trap*, *Ctsk*, *Atp6v0d2*, *Calcr*, *Nfatc1*, and *c-Fos* in BMMs treated with M-CSF (30ng/mL), RANKL (50ng/mL), and indicated DZNep concentrations for 5 days. Gene expression was analyzed by real-time PCR. mRNA expression levels were normalized relative to the expression of β -actin. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are expressed as median and interquartile range $\bar{x}$ n=3.

Figure 3

DZNep promoted osteoclast formation by inducing the p-P65 nuclear translocation. (A) NFATc1 and c-Fos expression levels in BMMs treated with or without 25 nM of DZNep for 0, 1, 3, and 5 days. (B) The gray levels of NFATc1 and c-Fos were quantified and normalized to β -actin using Image J. (C) NFATc1 and c-Fos expression levels in BMMs stimulated with M-CSF (30ng/mL), and RANKL (50ng/mL) for 5 days in presence of a various concentration of DZNep. (D) The gray levels of NFATc1 and c-Fos were quantified and normalized to β -actin using Image J. (E) BMMs were pretreated with 25 nM of DZNep for 3 hours

before the addition of RANKL for 30 min. Nuclear translocation of p-P65 was analyzed using western blotting. (F) RAW264.7 cells were pretreated with 25 nM DZNep for 2 hours, and then RANKL was added for 1 hour. Nuclear translocation of p-P65 was then visualized by immunofluorescence. Scale bar =20nM. (*p < 0.05; **p < 0.01; ***p <0.001; ****p <0.0001). Data are expressed as median and interquartile range n=3.

Figure 4

DZNep promoted the p-P65 nuclear by facilitating the phosphorylation of IKKα/β, and the degradation of IκBα instead of the MAPK pathway. (A) RAW264.7 cells were pretreated with 25 nM DZNep for 2 hours before the stimulation with RANKL for specific times, and the levels of NF-κB signaling pathway proteins were determined. (B) The gray levels of p-P65 was quantified and normalized to β-actin using Image J. (C) The gray levels of p-IκBα was quantified and normalized to β-actin using Image J. (D) RAW264.7 cells were pretreated with 25 nM DZNep for 2 hours before the RANKL was added on different time points, and the expression of MAPK signaling pathway proteins were explored. (E) The gray levels of p-ERK was quantified and normalized to β-actin using Image J. (*p < 0.05; **p < 0.01; ***p <0.001; ****p <0.0001). Data are expressed as median and interquartile range n=3.

Figure 5

DZnep activated the NF- κ B signaling pathway through EZH2-H3K27me3-Foxc1 axis. (A) BMMs cells were treated with or without 25 nM DZnep for 0, 1, 3, 5 days accompanied the stimulation of RANKL, and the levels of EZH2 and H3K27me3 were determined. (B) The gray levels of EZH2 and H3K27me3 were quantified and normalized to β -actin using Image J. (C) Expression of the Foxc1 in BMMs treated with M-CSF (30ng/mL), RANKL (50ng/mL), and indicated DZnep concentrations for 5 days. (D) BMMs cells were treated with negative control or different shRna of EZH2, and the levels of EZH2 were determined. (E) Expression of the Foxc1 in BMMs after treated with negative control or different shRna of EZH2. (F) BMMs were treated with negative control or shRna-2 of EZH2 and stimulated by M-CSF (30ng/ml) and RANKL (50ng/ml) for 5 days. Then the cells were fixed with 4% paraformaldehyde and stained for TRAP. Scale bar = 20 μ m. (G) Quantification of number of osteoclasts, area of osteoclasts. (H) BMMs were seeded onto the hydroxyapatite-coated Osteo Assay plates and cultured with M-CSF (30 ng/mL), RANKL (50 ng/mL), and with negative control or shRna-2 of EZH2 for 7 days. Scale bar = 20 μ m. (I) Quntification of bone resorption area were performed by ImageJ. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are expressed as median and interquartile range $\bar{x}$ n=3-4.

Figure 6

The effects of DZNep on osteoblastogenesis and co-cultivation system. (A) Cell viability of DZNep-treated BMSC was tested by CCK-8 at 12, 48, and 96 hours. (B) BMSC were treated with osteoblast-cultured medium, and with different concentrations of DZNep for 7 days. Then the ALP staining was performed after cells were fixed with 4% paraformaldehyde. Scale bar = 20 μ m. (C) Percentage of ALP+ area of total area was Quantified by Image J. (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$). (D) The

Alizarin Red staining was performed after BMSC were treated with osteoblast-cultured medium, and with indicated concentrations of DZNep for 28 days. Scale bar = 50μm. (E) Quantification of area of calcium deposition in the extracellular matrix. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). (F) ALP was detected after BMMs and Osteoblast precursor cells were co-cultivated in persence or absence of DZNep for 7 days. (G)Percentage of ALP+ area of total area was analyzed by Image J. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are expressed as median and interquartile range n=3-4.

Figure 7

DZNep promoted osteoblasts formation through the EZH2-H3K27me3-Wnt4 axis. (A) EZH2 expression levels in BMSC treated with 0, 25, 50, 100 nM of DZNep combined with osteoblast cultured medium for 24 hours. (B) The gray levels of EZH2 were quantified and normalized to β -actin using Image J. (C) H3K27me3 expression levels in BMSC treated with 0, 25, 50, 100 nM of DZNep combined with osteoblast cultured medium for 24 hours. (D) The gray levels of H3K27me3 were quantified and normalized to β -actin using Image J. (E) Expression of the wnt signaling pathway-specific genes Wnt1, Wnt6, Wnt10a, and Wnt4 in BMSC treated with 0, 25, 50, 100 nM of DZNep combined with osteoblast cultured medium for 24 hours. (F) Expression of the wnt signaling pathway-specific genes Wnt1, Wnt6, Wnt10a, and Wnt4 in BMSC treated with or without 100 nM of DZNep combined with osteoblast cultured medium for 7 days. (E) Expression of the osteoblast-genes Runx2, Ocn, Coll-1a, and Opn in BMSC treated with 0, 25, 50, 100 nM of DZNep combined with osteoblast cultured medium for 24 hours. (F) Expression of the osteoblast-genes Runx2, Ocn, Coll-1a, and Opn in BMSC treated with or without 100 nM of DZNep combined with osteoblast culture medium for 0 and 7 days. Gene expression was analyzed by real-time PCR. mRNA expression levels were normalized relative to the expression of β -actin. (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$). Data are expressed as median and interquartile range $\bar{x}$ ±n=3.

Figure 8

DZNep showed the therapeutic effect on bone defect in vivo. (A) The defect tibias of mice treated with or without DZNep were scanned with animal X-ray, and two-dimensional images are presented. (B) The fixed tibias of bone defect mice divided into two groups and treated for 2 weeks were analyzed by mCT, and three-dimensional reconstructed images are presented. Scale bar = 50 μ m. (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$). (C) Microstructural indices include bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp) obtained by analyzing the two mouse groups are presented. (D) H&E (magnification $\times 4$ and $\times 10$) staining,

respectively, of the defect tibia sections. Scale bar = 25 μm and 10 μm . (E) TRAP (magnification $\times 4$ and $\times 10$) staining, respectively, of the defect tibia sections. Scale bar = 25 μm and 5 μm . (F) The number of TRAP-positive cells and OcS/BS%. (G) Immunofluorescence staining, respectively, of Ocn in the defect tibiae sections. Scale bar = 25 μm . (H) Schematic representation of the molecular mechanism of the article (Created with BioRender.com). Data are expressed as median and interquartile range $n=3-6$.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [S1.jpg](#)